The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Annual Report

  December 17, 2019

CEO Comments

Read More
  Quarterly Report 1 19/20, January 22, 2020

Dear Shareholders and readers

I am proud to say that the first quarter of the financial year 2019/2020 has substantially strengthened Diamyd Medical as a company. Recent clinical results and analyses provide strong support for the efficacy of the diabetes vaccine Diamyd® and significantly decreases the risk in the clinical development program for our type 1 diabetes therapy.

Recent clinical results and analyses provide strong support for the efficacy of the diabetes vaccine Diamyd® and significantly decreases the risk in the clinical development program for our type 1 diabetes therapy.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
March 11 − March 12, 2020
Stockholm Corporate Finance Life Science seminar
March 25, 2020
Quarterly Report II
Quarterly Report 2 2019/2020
May 7 − May 8, 2020
Health Data Forum
Healthcare Summit, Cascais, Portugal
June 24, 2020
Quarterly Report III
Quarterly Report 3 2019/2020
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of December 30, 2019

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 556 223 7 333 040 14.30 35.69
Avanza Pension 9 260 821 13.39 10.05
Lindkvist, Bertil 6 370 000 9.21 6.91
Nordnet Pension 2 216 688 3.20 2.40
Hansen, Patrik 1 070 000 1.55 1.16
Swedbank Försäkring 1 040 046 1.50 1.13
Konstruktions o Försäljningsaktiebolag 750 000 1.08 0.81
Arandi Development AB 500 000 0.72 0.54
Relbo AB 475 550 0.69 0.52
Schelé, Sven 460 000 0.67 0.50
Remaining shareholders 37 137 428 53.7 40.3
Total 2 556 223 66 613 573 100.0 100.0

Order GAD for preclinical research

ORDER

Annual Report

  December 17, 2019
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research